GIAN PIERO FASOLA, M.D.; FRANCESCO D'OSUALDO, M.D.; VINCENZO DE PANGHER, M.D.; ENZO BARDUCCI, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Mexiletine, a primary amine that resembles lidocaine in chemical structure, is a new anti-arrhythmic agent without known haematologic side effects. Adverse reactions to the drug include only one case of thrombocytopenia (1). We report the case of a patient who developed thrombocytopenia after mexiletine administration.
On 18 June 1983, a 53-year-old man was hospitalized with heart failure and ischemic heart disease. Two platelet counts obtained 2 weeks and a few days before admission were normal (greater than 200 000/mm3). There was no history of drug allergy or thrombocytopenia, and no evidence of splenomegaly. Body temperature, erythrocyte sedimentation
FASOLA GP, D'OSUALDO F, DE PANGHER V, et al. Thrombocytopenia and Mexiletine. Ann Intern Med. 1984;100:162. doi: 10.7326/0003-4819-100-1-162_1
Download citation file:
Published: Ann Intern Med. 1984;100(1):162.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use